Designing medicine with machines

AI isn't just predicting drug outcomes, it's reprogramming the way therapies are discovered, tested, and delivered. Inside the engine room of drug innovation, algorithms are accelerating timelines and fixing inefficiencies, one insight at a time

- Ashok Pandey [e-mail]

For Yash Deshpandey, Heath Analyst and Prajakta Kulkarni, Assistant Vice President - Cognitive Solutions Delivery, Findability Sciences, Artificial Intelligence isn't a supporting act in drug discovery, it's the engine.

The journey from lab bench to bedside is long, costly, and often inefficient. But thanks to AI, what used to take years can now happen in months. Their team is pioneering a shift, using intelligent systems not only to discover better molecules but to break bottlenecks across the entire pharmaceutical value chain.

Rethinking discovery from the ground up

The early stages of drug discovery are notoriously slow. But with proprietary AI platforms scanning massive data sets from genomics and clinical trials to real-world evidence, Findability Sciences has flipped the pace.

Their AI doesn’t just analyze, it prioritizes. It hunts for viable targets with a speed and precision that dramatically outperforms traditional methods. The result? Up to 40% reductions in the time taken to identify promising drug candidates.

And that's not where the efficiencies end